publication venue for
- The therapeutic potential of vasopressin receptor antagonists in congestive heart failure.. 14. 2005
- Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.. 13. 2004
- Expanding indications of statins; implications of the Heart Protection Study.. 12. 2003
- Therapeutic developments in amyotrophic lateral sclerosis.. 8. 1999
- Clinical trials report on ongoing trials in lung cancer.. 6. 1997
- Docetaxel: a new active agent in the therapy of metastatic breast cancer.. 6. 1997
- The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727. 2012
- Is there a role for oral blockade of platelet glycoprotein IIb/IIIa receptors in coronary and cerebrovascular disease? 2003
- Rate control versus rhythm control for the management of atrial fibrillation: the verdict of the AFFIRM trial. 2003
- Cancer immunotherapeutics meeting. 2004
- Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials. 2022
- C-MET inhibitors for advanced non-small cell lung cancer. 2018
- Cefiderocol: a novel siderophore cephalosporin. 2018
- MEK inhibitors under development for treatment of non-small-cell lung cancer. 2017
- Drugs currently under investigation for the treatment of invasive candidiasis. 2017
- Ganetespib for small cell lung cancer. 2016
- Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. 2014
- Have we reached the limits for the treatment of diabetic nephropathy? 2014
- Capecitabine in the treatment of esophageal and gastric cancers. 2013
- IL-17 targeted therapies for psoriasis. 2013
- Small-molecule inhibitors of the human epidermal receptor family. 2009
- Corticorelin acetate injections for the treatment of peritumoral brain edema. 2009
- Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. 2009
- Raltegravir: an integrase inhibitor for HIV-1. 2008
- The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. 2008
- Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. 2008
- Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. 2007
- Sunitinib malate for the treatment of solid tumours: a review of current clinical data. 2006
- The benefits of abciximab questioned in percutaneous coronary interventions following pretreatment with high-dose clopidogrel. 2005
- Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials. 2004
- Angiotensin receptor blockers in acute myocardial infarction. 2004
- Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer. 2004
- Dopamine agonists in Parkinson's disease. 2003
- Progesterone antagonists and progesterone receptor modulators. 2003
- Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. 2003
- Novel therapeutic agents under investigation for malignant melanoma. 2003
- Selective aldosterone blockade with eplerenone in patients with congestive heart failure. 2003
- Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study. 2003
- What are the best first-line antihypertensives: answers and more questions from the ALLHAT study. 2003
- Clinical trials evaluating angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the setting of acute myocardial infarction. 2003
- Recent advances in the pharmacological treatment of colorectal cancer. 2003
- Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease. 2002
- Treprostinil therapy for pulmonary artery hypertension. 2002
- Therapeutic potential of H(3)-receptor agonists in myocardial infarction. 2000
- Targeted therapies for the myeloid leukaemias. 2000